{'fraction_non_alphanumeric': 0.02390057361376673, 'fraction_numerical': 0.0, 'mean_word_length': 5.6687898089171975, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
ARTERIAL CARBOXYHEMOGLOBIN CONCENTRATIONS AS A PREDICTOR OF CHEMOSENSITIVITY IN ELDERLY PATIENTS WITH ADVANCED LUNG CANCER

cyclophosphamide, doxorubicin, vincristine, and prednisone, with the addition of rituximab, is the standard treatment for non-Hodgkin’s lymphoma in older people. In conclusion, despite the perceived barriers to including elderly cancer patients in clinical trials, there are few data to support excluding them. The increasing use of a complete geriatric assessment can lead to a more individualized patient treatment plan. Furthermore, the enormous advances in supportive treatments over recent years enable adverse effects to be minimized. Moreover, the implementation of prospective trials is strongly recommended to assess properly the quality of life of elderly patients undergoing chemotherapy. In this way, it could be possible to counteract an unjustified ‘‘ageism’’: a prejudice that denies opportunities of treatment or even cure for patients that, as far as we know, may have the same chance as younger patients.